Our pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP), and is currently in late-stage clinical development for the prevention of migraine.
Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results
Data presented at American Academy of Neurology and American Headache Society Annual Meetings continue to support eptinezumab’s differentiated clinical profile and impact on... LEARN MORE
The U.S. Food and Drug Administration (FDA) accepted Alder’s Biologics License Application for eptinezumab in April 2019, with a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2020.